AbbVie Inc. (ABBV) earnings date
Feb 5, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 31 days, typically, give or take 3 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Fri, Oct 30, 2026 | before open | 30 | 8-K |
| Q2 FY2026 | Fri, Jul 31, 2026 | before open | 31 | 8-K |
| Q1 FY2026 | Wed, Apr 29, 2026 | before open | 29 | 8-K |
| Q4 FY2025 | Wed, Feb 4, 2026 | before open | 35 | 8-K |
| Q3 FY2025 | Fri, Oct 31, 2025 | before open | 31 | 8-K |
| Q2 FY2025 | Thu, Jul 31, 2025 | before open | 31 | 8-K |
| Q1 FY2025 | Fri, Apr 25, 2025 | before open | 25 | 8-K |
| Q4 FY2024 | Fri, Jan 31, 2025 | before open | 31 | 8-K |
What they guided beta
| Q3 FY2026 | "Raises 2026 Adjusted Diluted EPS Guidance Range from $13.76 - $13.96 to $13.95 - $13.99, which Includes an Unfavorable Impact of $0.69 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the Third Quarter 2026" exhibit |
| Q3 FY2026 | "Additional data from this study, including results from a 36-week blinded extension period, are expected next year and will be used to support regulatory submissions for lutikizumab in HS in the second half of 2027." exhibit |
| Q3 FY2026 | "The strategic relationship will pursue programs with first-in-class and best-in-class potential, combining Iambic's molecular superintelligence platform with AbbVie's therapeutic area expertise. 5 Full-Year 2026 Outlook AbbVie is raising its adjusted diluted EPS guidance for the full year 2026 from $13.76 - $13.96 to $13.95 - $13.99, which includes an unfavorable impact of $0.69 per share related to acquired IPR&D and milestones expense incurred year-to-date through the third quarter 2026." exhibit |
| Q3 FY2026 | "The company's 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the third quarter of 2026, as both cannot be reliably forecasted." exhibit |
| Q2 FY2026 | "Updates 2026 Adjusted Diluted EPS Guidance Range from $13.91 - $14.11 to $13.87 - $14.07; Now Includes a $0.14 per Share Dilutive Impact Related to the Proposed Acquisition of Apogee Therapeutics, Which is Anticipated to Close in the Third Quarter of 2026; Includes an Unfavorable Impact of $0.58 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the Second Quarter 2026 NORTH CHICAGO, Ill., July 31, 2026 – AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2026." exhibit |
| Q2 FY2026 | "The acquisition holds potential for substantial shareholder value creation, with mega-blockbuster peak sales potential across Apogee's pipeline of assets, and is expected to close in the third quarter of 2026." exhibit |
| Q2 FY2026 | "This approval gives clinicians an option to initiate treatment as soon as acute infection is confirmed and makes Maviret the only treatment approved in the EU for both acute and chronic HCV infection. 4 Full-Year 2026 Outlook AbbVie is updating its adjusted diluted EPS guidance to include the impact of the proposed Apogee Therapeutics acquisition, which is expected to be $0.14 dilutive in 2026, based upon an anticipated close in the third quarter of this year." exhibit |
| Q2 FY2026 | "As a result, AbbVie is updating its adjusted diluted EPS guidance range for the full year 2026 from $13.91 - $14.11 to $13.87 - $14.07, reflecting a change of $0.04 at the midpoint." exhibit |
| Q2 FY2026 | "The company's 2026 adjusted diluted EPS guidance includes an unfavorable impact of $0.58 per share related to acquired IPR&D and milestones expense incurred year-to-date through the second quarter 2026." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/ABBV
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/ABBV
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/ABBV/"><img src="https://veritasdata.dev/embed/ABBV.svg" alt="ABBV earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/ABBV/)
Script
<script async src="https://veritasdata.dev/embed/ABBV.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/ABBV"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.